{
    "id": 21136,
    "fullName": "MAP2K1 I111N",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "MAP2K1 I111N lies within the protein kinase domain of the Map2k1 protein (UniProt.org). I111N is predicted to confer a gain of function to the Map2k1 protein, as demonstrated by increased Map2k1 kinase activity in an in-vitro assay and is also associated with resistance to inhibitors (PMID: 12370306).",
            "references": [
                {
                    "id": 5157,
                    "pubMedId": 12370306,
                    "title": "Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12370306"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5604,
        "geneSymbol": "MAP2K1",
        "terms": [
            "MAP2K1",
            "CFC3",
            "MAPKK1",
            "MEK1",
            "MKK1",
            "PRKMK1"
        ]
    },
    "variant": "I111N",
    "createDate": "04/14/2016",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": {
        "id": 173416,
        "transcript": "NM_002755",
        "gDna": "chr15:g.66436786T>A",
        "cDna": "c.332T>A",
        "protein": "p.I111N",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12153,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28495,
                "profileName": "BRAF V600E MAP2K1 I111N"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12149,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",
            "molecularProfile": {
                "id": 28495,
                "profileName": "BRAF V600E MAP2K1 I111N"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10118,
                    "pubMedId": 28655712,
                    "title": "BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28655712"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21652,
            "profileName": "MAP2K1 I111N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28495,
            "profileName": "BRAF V600E MAP2K1 I111N",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 173416,
            "transcript": "NM_002755",
            "gDna": "chr15:g.66436786T>A",
            "cDna": "c.332T>A",
            "protein": "p.I111N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 173417,
            "transcript": "XM_017022411",
            "gDna": "chr15:g.66436786T>A",
            "cDna": "c.332T>A",
            "protein": "p.I111N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}